Why the study?
Does the geko™ electro-stimulation device prevent VTE and provide cost savings in patients at high risk of VTE where other prophylaxis methods are impractical or contraindicated?
Does the geko™ electro-stimulation device prevent VTE and provide cost savings in patients at high risk of VTE where other prophylaxis methods are impractical or contraindicated?
NICE recommends the geko™ electro-stimulation device for VTE prophylaxis in high-risk patients where standard methods are impractical or contraindicated, estimating cost savings of £197 per patient.
Answers are grounded in this paper and cite their sources.
Supports geko™ adoption for VTE prophylaxis where standard methods are contraindicated; extends cost-effectiveness evidence for neuromuscular stimulation in guidelines.
The geko™ device is a single-use, battery-powered, neuromuscular electrostimulation device that aims to reduce the risk of venous thromboembolism (VTE). The National Institute for Health and Care Excellence (NICE) selected the geko™ device for evaluation, and invited the manufacturer, Firstkind Ltd, to submit clinical and economic evidence. King's Technology Evaluation Centre, an External Assessment Centre (EAC) commissioned by the NICE, independently assessed the evidence submitted. The sponsor submitted evidence related to the geko™ device and, in addition, included studies of other related devices as further clinical evidence to support a link between increased blood flow and VTE prophylaxis. The EAC assessed this evidence, conducted its own systematic review and concluded that there is currently limited direct evidence that geko™ prevents VTE. The sponsor's cost model is based on the assumption that patients with an underlying VTE risk and subsequently treated with geko™ will experience a reduction in their baseline risk. The EAC assessed this cost model but questioned the validity of some model assumptions. Using the EACs revised cost model, the cost savings for geko™ prophylaxis against a 'no prophylaxis' strategy were estimated as £197 per patient. Following a second public consultation, taking into account a change in the original draft recommendations, the NICE medical technologies guidance MTG19 was issued in June 2014. This recommended the adoption of the geko™ for use in people with a high risk of VTE and when other mechanical/pharmacological methods of prophylaxis are impractical or contraindicated in selected patients within the National Health Service in England.
No takes yet. Share an insight, caveat, or question.
Summers et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: